Seeking Alpha

FocalPoint Anal...'s  Instablog

FocalPoint Analytics
Send Message
I own and operate an analytical services/ research company.
My book:
The Internet in Everyday Life (Chapter 19)
  • Swine Flu AND Medical News Concentrator April 25, 2013 To July 6, 2013. 173 comments
    Apr 25, 2013 6:16 PM

    This instablog is designed as an interactive News Concentrator devoted to news and discussions about Swine Flu and other medical news.

    The top portion of the instablog contains useful background information/ charts.

    Up-to-date news content is posed in the comments area. So if you are interested in current news, read the comments.

    _____________________

    Update History:
    Added definition of Reassortment
    Added definition of R0 (R Naught)
    Added Overview of H1N1 / Categories of Vaccine Investment Plays Added Memory Alpha
    Added Link to Google's Swine Flu Infection Map
    Added Red Cross Tips for Dealing With The Flu
    Added definition of EUA and PREP act
    Broke Swine Flu Concentrator into two parts for October
    Broke Swine Flu Concentrator into three parts for October
    Added Swine Flu Concentrator November Part 1
    Bolded References to Older Swine Flu Concentrators in Memory Alpha
    Expanded the list of stocks discussed in the tags
    Alphabetized stocks in the tags
    Updated the play by stock list
    Added a table that contains the web site addresses for the companies discussed
    Moved links over one month old to the new Memory Alpha Reference Library
    Added definitions of Clinical Trials and Protocol.
    Corrected Roche stock symbol in the web site table
    _____________________
    Last Swine Flu News Concentrator Links:

    Swine Flu AND Medical News Concentrator January 1, 2013 to April 25, 2013:

    seekingalpha.com/instablog/283977-focalp...-13252151

    Swine Flu AND Medical News Concentrator October 13, 2012 To December 31, 2012.

    tinyurl.com/agndtk4

    Swine Flu News Concentrator June 13, 2012 to October 13, 2012

    tinyurl.com/9l3u3d6

    Swine Flu News Concentrator July 30, 2011 to June 13, 2012tinyurl.com/6nfvspe

    Swine Flu News Concentrator May 12, 2011 to July 29, 2011tinyurl.com/3m7hcfp

    Swine Flu News Concentrator March 22, 2011 to May 12, 2011
    tinyurl.com/3hgogm4

    Swine Flu News Concentrator February 20, 2011 to March 22, 2011
    tinyurl.com/4unv2hy

    Swine Flu News Concentrator January 28, 2011 to February 20, 2011
    tinyurl.com/4u9nlrz

    Swine Flu News Concentrator January 11, 2011 to January 28, 2011
    tinyurl.com/4maxxdv

    Swine Flu News Concentrator December 18 (2010) to January 11, 2011
    tinyurl.com/4gs9xzl

    Swine Flu News Concentrator November 11 (2010) to December 18, 2010
    tinyurl.com/22pykd8

    Swine Flu News Concentrator September 23 to November 11 (2010)
    tinyurl.com/29eflnpJ

    Swine Flu News Concentrator June 14 to September 23 (2010)
    http://tinyurl.com/294bzc6

    Swine Flu News Concentrator April 8 to June 14
    tinyurl.com/25lqvfx

    Swine Flu News Concentrator (March 13 - April 8)
    tinyurl.com/y8w7mgy

    Swine Flu News Concentrator (February 12 - March 13)
    tinyurl.com/ykba7dl

    Swine Flu News Concentrator January 25 to February 12
    http://preview.tinyurl.com/yjccho4

    ___________________
    Some Definitions:

    What is Reassortment

    When two different virus strains infect the same host, they often exchange genes, a process known as reassortment.

    A significant number of experts are concerned that as H5N1 (Avian Flu) spreads more widely and infects more people, it will come across more hosts who are also carrying human flu viruses. This increases the likelihood of a new strain emerging that has the severity of the bird flu virus and the infection rate of the swine flu virus, leading to a new global pandemic with much deadlier consequences than the one we are experiencing at the moment.

    What is R naught (R 0)

    How many people the average infected person infects is called the basic reproductive number, or R0 (pronounced "R naught").

    Measles, which is probably mankind's most contagious infection, has an R0 of about 18. Polio's number is about 6; severe acute respiratory syndrome (SARS) about 5. For seasonal flu strains, the R0 is about 1.2, and for pandemic strains it is rarely higher than 2. For the novel H1N1 strain, it's about 1.6. What this low R0 means is that flu outbreaks are always teetering on the verge of having their myriad chains of transmission broken by people who get infected but don't pass the virus to anyone else.

    Swine Flu - Novel H1N1 flu, popularly known as swine flu, is a respiratory infection caused by an influenza virus first recognized in spring 2009. The new virus, which is officially called swine influenza A (H1N1), contains genetic material from human, swine and avian flu viruses. (By Mayo Clinic staff)

    Pandemic - The word "pandemic" comes from the Greek "pan-", "all" + "demos", "people or population" = "pandemos" = "all the people." A pandemic affects all (nearly all) of the people.

    A World Health Organization phase 6 pandemic indicates that influenza due to the novel H1N1 swine flu is occurring in multiple countries around the world and that human infection is widespread. The classification does not reflect the severity of individual infections.

    Cytokine Storm -
    When our body detects foreign micro-organisms indicating an infection, our body might respond by over-protecting the site of infection. The body may race so many antibodies to the infection site that they collect in what is known as a cytokine storm.

    A cytokine storm, or "Hypercytokinemia" is a potentially fatal immune reaction consisting of a positive feedback loop between cytokines and immune cells.
    www.wisegeek.com/what-is-the-cytokine-st...

    A positive feedback loop means that as something increases, that increase stimulates further growth.

    What makes younger people more susceptible to H1N1 is that their "vigorous immune systems pour out antibodies to attack the new virus. That can inflame lung cells until they leak fluid, which can overwhelm the lungs.

    This vulnerability in the young is reminiscent of the Spanish flu of 1918. That strain of flu also struck mostly healthy young adults.

    Pulmonary Embolism - Occurs when a blood clot forms in an arm or leg breaks free and enters the lungs where it is too large to pass through the small vessels of the lungs and forms a blockage. This stops blood from flowing into an area of the lung, and the part of the lung dies because it does not receive oxygen.
    medicalnewstoday.com/articles/153796.php

    What is an Emergency Use Authorization (EUA)?
    An EUA may be issued by the Food and Drug Administration (FDA) to allow either the use of an unapproved medical product or an unapproved use of an approved medical product during certain types of emergencies with specified agents.

    What is the PREP Act?
    The PREP Act authorizes the Secretary of the Department of Health and Human Services ("Secretary") to issue a declaration ("PREP Act declaration") that provides immunity from tort liability (except for willful misconduct) for claims of loss caused, arising out of, relating to, or resulting from administration or use of countermeasures to diseases, threats and conditions determined by the Secretary to constitute a present, or credible risk of a future public health emergency to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures.

    The PREP Act also authorizes an emergency fund in the United States Treasury to provide compensation for injuries directly caused by administration or use of a countermeasure covered by the Secretary's declaration. While no funds have been appropriated for this purpose, if funds are appropriated, compensation may then be available for medical benefits, lost wages and death benefits to individuals for specified injuries.
    cdc.gov/h1n1flu/eua/qa.htm

    What are Clinical Trials:
    Clinical trials, also known as clinical studies, are research studies in which scientists and doctors test new drugs and treatments to see if they will improve health. Many of today's treatments for cancer are based on the results of past clinical trials. Because of progress made through clinical trials, many people treated for cancer are now living longer.

    Clinical trials are divided into four phases.
    Phase 1 trials: These trials are the first time a new drug or treatment is given to humans. They are normally carried out in a small number of volunteers (typically 6-20 people) who may include healthy volunteers or patients with the disease for which the product is intended as a treatment in order to find out how safe the treatment is. They also look at how a new drug should be given (by mouth, injected into muscle or the bloodstream, etc.), how often and at what dose. Phase 1 trials can also involve patients for whom standard therapies have failed and for whom no other therapies are available.

    Phase 2 trials: These trials involve larger numbers of people (typically 12 - 50). Phase 2 trials continue to look at safety of the therapy but also test how well the new drug or treatment works in patients with different disease types.

    Phase 3 trials: These are large studies (100+ people) that look at how well a new drug or treatment works in comparison to current therapies to see which treatment is better. Those taking part are usually divided into two treatment groups: standard treatment versus new treatment.

    Phase 4 trials: These trials are usually carried out after the drug or treatment has been approved by the FDA and is readily available for use in the general patient population. The purpose of Phase 4 trials is to continue to study the effects of the drug or treatment on different populations and to look for side effects associated with long-term use.
    Back to Top

    What is a Protocol:
    Clinical trials use written guidelines called protocols. The protocol explains what the trial hopes to accomplish, how the trial will be carried out, and why each part of the trial is necessary. For example, the protocol includes:

    * The reason for doing the trial
    * How many people will be in the trial
    * Who is eligible to take part in the trial
    * What study drugs participants will need to take
    * What medical tests participants will have and how often
    * What information will be gathered

    Every doctor or research center that takes part in the trial uses the same protocol. This makes sure that patients are treated identically no matter where they are receiving treatment, and that information from all the centers taking part can be combined and compared.

    Why Slow Production for Traditionally Produced (chicken eggs) Swine Flu Vaccine:
    One dose of swine flu vaccine for every two eggs, compared with two doses of
    seasonal flu vaccine per egg

    Sorry if the link does not work... it appears the Boston Globe newspaper appears to be playing games with link addresses... Just copy the link, and Google it.

    http://www.boston.com/business/healthcare/articles/2009/10/22/quest_for_swine_flu_vaccine_giving_some_firms_a_boost/

    _____________________
    Brief Overview of Categories of H1N1/ Vaccine Investment Plays:

    I - Vaccines / Prevention
    1) Production Method / Capacity plays (NASDAQ:NVAX) (NASDAQ:VICL) (NYSE:NVS) (NASDAQ:INO) (NYSE:CSL)
    2) Nationalistic / Population Size Play (SVA - China) (NVAX - India)
    3) Injection / Vaccine support services (syringes etc.) (NYSE:BAX) (NYSE:BDX)
    4) Outsourced production plays
    5) Bio -Defense (MDCGF - France)
    6) Anti-Mutation / Pan-Influenza Play (NYSEMKT:CVM) (NYSEMKT:NNVC) (INO)
    7) Universal Flu Vaccine Play (INO)

    II - Treatment After Infection Occurs:
    1) Dealing with severe lung infections (Fludase® (DAS181)) (NYSE:CBM) (OTCQB:AEMD)
    2) ICU treatments (NASDAQ:BCRX) (NYSE:GSK) (NYSE:ROG)
    III - Population Avoidance:
    1) masks/ disinfectants… Surgical masks are good enough (NYSEMKT:APT) (NYSE:MMM) (NYSE:CLX) (NYSE:ECL) (OTCQB:PURE)

    IV - Testing do you have it? (NASDAQ:GPRO)
    1) Test kits - (NYSE:DGX)

    V - Merger / Acquisitions / Licensing (VICL) (NVAX)
    _____________________
    Sorry this is still a graphic instead of a table. I played with the table tool, but its a
    PITA to work with.

    Swine Flu Companies Discussed and Their Web Sites

    _____________________
    Swine Flu Hits Stuffed Animal World:

    2011 H1N1 US Flu Outbreak Map:
    Here is a link that gives information by US states. The Link is from DoubleGuns
    tinyurl.com/6khyjq
    ___________________

    Red Cross Tips For Dealing With The Flu:

    IF YOU ARE ILL -
    * Stay in a room separate from common areas of the home and avoid contact with others as much as possible.

    * Stay at home for at least 24 hours after their fever is gone without using medicine to reduce the fever.

    * Get lots of rest and drink plenty of fluids.

    * Consider wearing a face mask, if available and tolerable, when sharing common spaces with household members. (ed - surgical masks ok).

    * Check with your healthcare provider about whether to take antiviral medication, or if fever persists, whether antibiotics are needed.

    WHEN CARING FOR SOMEONE WHO HAS THE FLU -
    *Disinfect door knobs, switches, handles, toys and other surfaces that everyone touches.

    * Use detergent and very hot water to do dishes and wash clothes. It's okay to wash everyone's dishes and clothes together. Wash your hands after handling dirty laundry.

    * Designate only one adult as the caregiver. People at increased risk of severe illness from the flu should not be caregivers.

    * Although not mentioned by the Red Cross, the caregiver should probably ware a surgical mask as well when entering the sick room.

    * Deal with crisis situations calmly and confidently to give the best support to the person being cared for.
    _____________________

    MayoClinic.com Provides Credible, Up-to-Date Information And Decision-Support Tools For Flu Season

    Click here to link to the Mayo tool:
    www.mayoclinic.com/health/flu-symptoms/F...

    _____________________
    Suggested Protocol For Schools To Decide When Flu Should Trigger A Shutdown
    www.medicalnewstoday.com/articles/169984.php

    After comparing more than two dozen possible scenarios for closing a school, the analysis suggested three optimal scenarios:

    1. A single-day influenza-related absentee rate of 5 percent

    2. Absenteeism of 4 percent or more on two consecutive days

    3. Absenteeism of 3 percent or more on three consecutive days

    Disclosure: (sometimes trading, sometimes holding)

    Disease outbreak map on Globalincident.com

    tinyurl.com/c8f3do

    Link from Guns and OG.

Back To FocalPoint Analytics' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (173)
Track new comments
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    FPA; Haven't said thanks in a long time! Shame on me!

     

    Thanks for keeping this running, the great info in the headers, and for being a general all-around nice guy!

     

    HardToLove
    25 Apr 2013, 06:43 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    I 2nd that
    25 Apr 2013, 08:38 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Since we have a motion and a 2nd I move that the motion is approved!!!
    26 Apr 2013, 09:48 AM Reply Like
  • Mercy Jimenez
    , contributor
    Comments (2028) | Send Message
     
    Motion passes unanimously!!
    26 Apr 2013, 09:54 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    China bird flu keeps growing at 120 now :

     

    http://onforb.es/10KNzMp
    28 Apr 2013, 05:55 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Hunan province confirms it's first case:
    http://bloom.bg/1278Gmf
    28 Apr 2013, 06:11 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    H7N9 Vaccine At Least 6 Weeks Away

     

    http://bit.ly/14zAaI1

     

    "Chinese officials suspect there may be cases of human-to-human transmission, which would be necessary for the outbreak to rise to pandemic levels. So far, the strain has infected 108 people, 22 of whom have died. If the strain proves to be a candidate for a pandemic outbreak, it might be a while before health professionals have a vaccine to protect against the strain, according to Joseph Kim, president of Inovio, a California-based company that is currently in the initial stages of developing an H7N9 vaccine."

     

    (INO) another penny stock to watch.
    28 Apr 2013, 09:50 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    INO is on my watch list, and that number of infected is now 124 with 24 deaths and probably growing.

     

    First company to ship vaccines or treatment should pop.
    28 Apr 2013, 10:23 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Novartis also working on the vaccine.

     

    http://bit.ly/16cgvgW

     

    Looks like with a bird flu virus there are additional difficulties using eggs to create the vaccine.

     

    http://bit.ly/14zAaI1

     

    The traditional method of creating vaccines uses chicken eggs to create doses of the vaccine, which proved troublesome while scientists were trying to create an H5N1 bird flu vaccine in 2009. Kim warns that researchers might have similar problems creating an H7N9 vaccine because both H5N1 and H7N9 infect chickens.

     

    "The H5N1 viruses proved very pathogenic to the vaccine grown in eggs, so we had huge trouble growing them to make the vaccines," he says. "H7N9 could be similar – if we're making conventional pandemic flu vaccines using eggs, we might face challenges."
    29 Apr 2013, 10:02 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Another great article on what is happening in Taiwan and the rush to create a vaccine there with their biotech companies.

     

    http://bit.ly/11wHwGg

     

    They mention potential egg shortages if chickens are culled to prevent spread of disease so using the egg method to create vaccine is more risky.
    29 Apr 2013, 10:04 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    There are newer technologies for growing or manufacturing vaccine products that do not use the tried and true chicken egg process. However, I am uncertain if any of them are developed to the scale needed to address a pandemic in the way the big manufacturers can scale up the egg process.

     

    Here are a couple of discussions of the newer technologies:

     

    http://1.usa.gov/13G7j0e

     

    http://bit.ly/ZL74CM

     

    As mentioned above, Novartis is in the game with canine kidney cell technology for its newest flu vaccine, announced last fall: http://bit.ly/13G7lp8

     

    From the prescribing info:
    "FLUCELVAX (Influenza Virus Vaccine), a vaccine for intramuscular injection, is a “subunit” influenza virus vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line. These cells were adapted to grow freely in suspension in culture medium. The virus is inactivated with ß-propiolactone, disrupted by the detergent cetyltrimethylammonium bromide and purified through several process steps. Each of the 3 virus strains is produced and purified separately then pooled to formulate the trivalent vaccine."

     

    Does anybody know if the canine kidney cell system is their plan for the H7N9 vaccine? Or would they use the traditional chicken egg method?
    29 Apr 2013, 10:37 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    This is what I found.They appear to be using synthetic biology to create the virus but it does not say how they are developing the vaccine.

     

    This new, faster approach is the result of a collaboration among the U.S. government, vaccine maker Novartis and a unit of the J. Craig Venter Institute, which is using synthetic biology - in which scientists take the genetic code of the virus and use it as a recipe to build the virus from scratch.

     

    http://huff.to/11QsNYt
    29 Apr 2013, 10:51 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Oops missed this. Dog kidney cells.

     

    That's when Novartis and Venter's company, Synthetic Genomics Vaccines Inc, went to work. By Thursday, April 4, they had synthetic DNA ready and had started to grow the virus in dog kidney cells.
    29 Apr 2013, 10:53 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    That HuffPo link is a bit ambiguous about whether the canine kidney cell process would actually be used for full scale manufacturing or is still in the experimental stage for H7N9.

     

    "When the genetic sequence for the virus became available on March 30, Robinson said, U.S. health officials decided to try the new synthetic biology technique to try to speed the process. That's when Novartis and Venter's company, Synthetic Genomics Vaccines Inc, went to work. By Thursday, April 4, they had synthetic DNA ready and had started to grow the virus in dog kidney cells."

     

    So they have started experimenting.

     

    But: "Shaw said the CDC plans to take a vaccine candidate at least to the stage of human safety trials" suggests it would need phase II type trials before it could be marketed, which would not be a six-week process.
    29 Apr 2013, 10:59 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    No doubt they can have the vaccine sooner than we think, but to manufacture it on a scale to vaccinate a billion people is another story.
    29 Apr 2013, 10:55 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    I can not imagine how long it would take to manufacture anything in the billions. Mind boggling. Then ship it. Then inject it. Your talking about the number billion several times. Just load 1 billion needles on 1 billion syringes. Yep doing any of that 1 billion times gets mind boggling.
    29 Apr 2013, 04:35 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    They may skip the animal testing and move to treatment immediately after developing a vaccine.

     

    Under normal circumstances, the path from animal testing to "small scale human tests" to full approval takes another couple months "in an accelerated path," Kim says. But in the case of a pandemic, the animal testing stage is sometimes skipped and the vaccine is immediately used to treat humans.

     

    http://bit.ly/14zAaI1
    29 Apr 2013, 01:28 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Hedge funds buying these 3 bio's: NVAX,

     

    http://seekingalpha.co...
    1 May 2013, 12:22 PM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    LT: That must explain the price tanking! The hedegies are probably shorting the crap out of it to drive price down before they buy in. I'll have to check the options to see if that's their tool ... not today - no volume and both calls and puts don't have any really outsized OI.

     

    Short volume up 31% since 2/28 though. So probably driving price down to cover as well.

     

    SWAG,
    HardToLove
    1 May 2013, 12:32 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    SAN DIEGO, May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company
    commercializing and developing products for the treatment of central nervous system disorders and
    pain, today announced positive top-line results from its extended Phase 1 clinical trial of
    Relday, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of
    risperidone for the treatment of schizophrenia. If approved, Relday has the potential to be the
    first subcutaneous antipsychotic product that allows for once-monthly dosing. Efforts are now
    underway to secure a strategic development and commercialization partner for Relday.
    The extended Phase 1 clinical trial included a 100 mg dose of Relday, following previously
    reported positive results with 25 and 50 mg doses
    http://bit.ly/104JQ53
    . The results for the 100 mg dose showed that risperidone blood concentrations in the therapeutic
    range were achieved on the first day of dosing, and maintained throughout the one-month period. In
    addition, dose proportionality has now been established across the full dose range that would be
    anticipated to be used in clinical practice (50 to 100 mg). The 100 mg dose was safe and
    well-tolerated, with no unexpected adverse events, including injection site reactions, as compared
    to the initial Phase 1 clinical trial with the 25 and 50 mg doses. The adverse events were
    generally mild to moderate and consistent with other risperidone products.
    "With the positive top-line results from the Relday Phase 1 extension, we believe that we have now
    confirmed the product candidate's viability across the anticipated commercial dosing range," said
    Stephen Farr, Ph.D., president of Zogenix. "We are well positioned to begin a multi-dose clinical
    trial to provide steady-state pharmacokinetic and safety data, once a partner is secured, prior to
    initiating Phase 3 development studies."
    Roger L. Hawley, chief executive officer of Zogenix, said, "We now have sufficient data to
    formalize our business development discussions, with a goal of securing a strategic development
    and commercialization partner. While we plan to retain U.S. rights to Relday, based on the
    505(b)(2) NDA regulatory pathway and previous discussions, we believe there is strong partnering
    interest in Relday."
    In connection with these partnering activities, Zogenix has retained Locust Walk Partners of
    Cambridge, MA, a transaction advisory firm for life sciences companies, to provide exclusive
    transaction advisory and support services. For information about Relday partnering opportunities,
    contact Jay Mohr, Managing Director, at (617) 300-0174, jay@locustwalkpartners...
    http://bit.ly/10Y8xaH
    .
    Risperidone is one of the most widely prescribed medications used to treat the symptoms of
    schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable
    antipsychotic market was approximately $2 billion in 2011. The leading injectable product in the
    category requires twice-a-month dosing, intramuscular injection and drug reconstitution prior to
    use. The combined market for oral and injectable antipsychotic products was estimated at more than
    $17 billion in 2011.
    About ReldayTM
    If approved, Relday has the potential to be the first subcutaneous antipsychotic product that
    allows for once-monthly dosing. Zogenix believes that Relday will offer an improved
    pharmacokinetic (PK) profile, significant reduction in injection volume and a simplified dosing
    regimen (e.g., no need for loading dose) due to DURECT's (Nasdaq:DRRX) SABER? controlled-release
    depot technology. In July 2011, Zogenix licensed from DURECT exclusive global rights to develop
    and commercialize this proprietary formulation which utilizes DURECT's SABER? depot technology.
    The Phase 1 clinical trial for Relday was conducted as a single-center, open-label, safety and PK
    trial of 40 patients with chronic, stable schizophrenia or schizoaffective disorder across a dose
    range of 25, 50 and 100 mg.
    About Zogenix
    Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a
    pharmaceutical company commercializing and developing products for the treatment of central
    nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL DosePro
    (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute
    treatment of migraine and cluster headache. Zogenix's lead investigational product candidate,
    Zohydro ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths
    of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the
    clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a
    New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday,
    is a proprietary, long-acting injectable formulation of risperidone for the treatment of
    schizophrenia; an investigational new drug application was submitted to the FDA in May 2012.
    Forward-Looking Statements
    Zogenix cautions you that statements included in this press release that are not a description of
    historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans,"
    "expects," "indicates," "will," "intends," "potential," "suggests," "assuming" and similar
    expressions are intended to identify forward-looking statements. These statements are based on the
    company's current beliefs and expectations. These forward-looking statements include statements
    regarding delivery and dosing benefits of Relday to both the patient and clinician, the viability
    of Relday, initiation of a multi-dose clinical trial and Phase 3 development studies for Relday,
    discussions with potential partners for rest-of-world development and commercialization of Relday,
    the interest in Relday by potential partners, the introduction of DosePro technology and the
    timing thereof, the ability of such product to address the global anti-psychotic market, and the
    ability to develop a once-monthly injectable product with improved pharmacokinetics and
    significant reduction in injection volume. The inclusion of forward-looking statements should not
    be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results
    may differ from those set forth in this release due to the risk and uncertainties inherent in
    Zogenix's business, including, without limitation: the uncertainties associated with the clinical
    development and regulatory approval of product candidates such as Relday, including potential
    delays in enrollment and completion of clinical trials; Zogenix's dependence on its collaboration
    with DURECT Corporation to develop Relday; inadequate therapeutic efficacy or unexpected adverse
    side effects relating to Relday that could prevent its development or commercialization;
    difficulties in identifying, negotiating, executing and carrying out strategic transactions
    relating to Relday; the terms of any development or commercialization partnership for Relday may
    not be favorable, and the partner may not perform as expected; the market potential for
    anti-psychotics, and Zogenix's ability to compete within that market; Zogenix's ability to obtain
    and the validity and duration of patent protection and other intellectual property rights for
    Relday; and other risks described in the company's prior press releases and filings with the
    Securities and Exchange Commission.
    You are cautioned not to place undue reliance on these forward-looking statements, which speak
    only as of the date hereof, and Zogenix undertakes no obligation to revise or update this release
    to reflect events or circumstances after the date hereof. All forward-looking statements are
    qualified in their entirety by this cautionary statement. This caution is made under the safe
    harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
    SUMAVEL?, DosePro?, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.
    SABER? is a trademark of DURECT Corporation.
    CONTACT: Investors
    Zack Kubow
    2 May 2013, 07:33 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Bird flu likely to appear in Europe and other places.

     

    Nicoll noted that genetic analysis studies of H7N9 samples taken from patients in China showed the virus had already acquired two genetic mutations that made it more likely to be able to become transmissible between people.

     

    Flu experts speaking at a briefing in London on Wednesday said those mutations, together with evidence that H7N9 is still mutating rapidly and probably spreading almost invisibly among birds because it does not make them obviously sick, meant this new flu was a "serious threat" to world health.

     

    http://fxn.ws/133db54
    2 May 2013, 05:11 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Is anyone familiar with Greffex?

     

    "Aurora company creates first H7N9 avian influenza vaccine"

     

    http://on9news.tv/Yj6yKg
    3 May 2013, 09:02 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    They must be way ahead of the crowd. Never heard of them before.
    3 May 2013, 09:26 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    NVAX - this is the best article I have seen for a short history & where they are today.

     

    http://seekingalpha.co...
    3 May 2013, 08:25 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Bird Flu: H7N9 Infection Risk Mapped

     

    http://bit.ly/13lQAA3

     

    The scientific article on which this was based is available online:
    http://bit.ly/11NJous

     

    Scroll down to look at the graphics demonstrating progression over time. As birds migrated north through the spring, the risk followed them from southern provinces to northern.Elegant scientific modeling.
    6 May 2013, 09:43 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    SMaturin: A fun read is the comments in the first link that say the U.S. is responsible for developing this and other flu variations. Looks fairly "official" to me. Government propaganda, no doubt.

     

    HardToLove
    6 May 2013, 09:59 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Wow, that tin foil hat is way too heavy for my skull!
    6 May 2013, 10:57 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    There is no way the tin foil could stand up to the heat in that guys head.
    6 May 2013, 05:48 PM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    (NVAX): Novavax Reports First-Quarter 2013 Financial Results

     

    http://bit.ly/12aiJJW

     

    And, misses on revenues, down 17.5%, getting $3.83MM vs expected $5.54MM and misses on EPS ($0.01) at ($0.07) vs. expected ($0.06).

     

    HardToLove
    7 May 2013, 08:28 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    New VLP vaccine candidate produced for H7N9 virus

     

    http://bit.ly/13ynjCj

     

    "To our knowledge, Medicago is the first to produce a VLP vaccine candidate against this potential pandemic strain demonstrating our ability to be a first responder in a pandemic scenario," said Andy Sheldon , President and CEO of Medicago. "Current influenza egg based vaccine manufacturers can take up to six months to produce a vaccine for any new strain, we have proven once again that we can cut this development time drastically.This combined with our vaccine production capacity at our pilot facility in Canada and our commercial facility in North Carolina and our best-in-class efficacy results for our H5N1 vaccine, strongly positions Medicago as a key player in addressing a potential pandemic."

     

    .........................

     

    Questions Remain About H7N9 Bird Flu Strain As 4 More Die Of Virus In China

     

    http://bit.ly/16gWrKP
    8 May 2013, 10:01 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    US invokes emergency act to keep H7N9 flu at bay

     

    http://bit.ly/ZKmGC1

     

    >>THE US government has declared that H7N9 bird flu "poses a significant potential for a public health emergency", and has given "emergency use authorisation" for diagnostic kits for the virus. This means tests can be used that haven't gone through the usual lengthy approval process by the US Food and Drug Administration.<<

     

    But no mention of who may be manufacturing the expedited diagnostic kit.

     

    >>
    The next emergency authorisation is likely to be for immune-stimulating chemicals called adjuvants to put in those vaccines. These were used in vaccines in Europe and Canada during the 2009 pandemic, but adjuvants suitable for flu are not currently approved in the US.

     

    Labs are now making "seed" viruses for manufacturers to create H7N9 vaccine. That process faces the same development delays as in 2009, when vaccine arrived too late for most people.

     

    But there is another problem: H7 flu is poor at stimulating immunity. Virologists at the European Flu Summit in Brussels last week told New Scientist that early results show 13 times more H7N9 virus is needed to elicit a protective immune response than is needed for ordinary flu. That's bad news: the more virus a vaccine requires, the fewer doses that can be grown in a given time.

     

    "H7N9 may be a 'stealth' virus that is able to fly under the immune system's radar," says Anne De Groot of the University of Rhode Island at Providence. That's because its surface protein haemagglutinin doesn't contain many short amino acid sequences – called epitopes – that trigger helper T-cells in the body to stimulate antibody-making cells.

     

    "H7N9 is not very immunogenic, because the epitopes have a very weak signal," says Masato Tashiro, head of flu at Japan's National Institute of Infectious Diseases in Tokyo. People differ genetically in the epitopes their T-cells recognise, and his lab has found that Asian people could be especially vulnerable.

     

    Adjuvants might make vaccines containing less virus more effective, meaning doses can be produced faster. However, children in northern Europe who received adjuvanted flu vaccines in 2009 had slightly higher rates of narcolepsy than normal. Epidemiological studies so far do not show whether the adjuvant was the cause, says Miriam Sturkenboom of Erasmus Medical Center in Rotterdam, the Netherlands. The US is now funding a large study of countries that used adjuvanted vaccines in 2009 to see if they may have caused narcolepsy.
    <<
    9 May 2013, 09:56 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    SMaturin: If (NVAX) isn't all over this, the mgmt. should be caned!

     

    They have the VLP capability, the production capacity, ... and demonstrated adjuvant safety, thus far.

     

    If various emergency orders are going to be issued, they ought to be able to proceed quite quickly to something proven safe and effective based on what's been seen in their other VLP trials.

     

    HardToLove
    9 May 2013, 10:29 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Yes, I agree they should be in a good position to get emergency approval for an H7N9 vaccine. But I have not seen any public announcement of such.

     

    CEO said this in the earnings call this week:

     

    "As we read about new strains of viruses that are being reported, with H7N9 in China and with the coronavirus being reported in Saudi Arabia, we are aware of the potential importance of our VLP platform. As part of our ongoing pandemic program, I can now report that we have made a VLP vaccine candidate for both of these pathogens. We will watch very closely the progress of these outbreaks and report on our plans, as they develop."

     

    For comparison, Medicago has already publicized emergency approval status: http://bit.ly/12iSXSL

     

    http://bit.ly/YwGtrc
    9 May 2013, 11:14 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    They cant even play designated hitter if they aren't at the ball park. Guess they will not be playing ball.
    9 May 2013, 11:28 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    I have been watching NVAX for some time now, but from the sidelines. It has been on a downturn recently, but I am considering starting a small position as a spec, given their position as a manufacturer ready to go if the CDC gives them the word.

     

    Medicago had a remarkable pop yesterday on its announcement, and it is a penny player.
    9 May 2013, 11:35 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    I (unfortunately) have NOT been on the sidelines. I need more than a pop and remarkable would not do it either. Fantastic AND explosive would be a good start.
    9 May 2013, 11:40 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    I own a small position left from an earlier trade when it really popped up.
    Trying to decide if I should add to it and also how to play this new flu. the big boyz are all over it, and could drown out the little guys is my fear.
    9 May 2013, 11:52 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    LT we must be in the same boat. Ahoy matey.
    9 May 2013, 01:50 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    CDC continues to build defenses in H7N9 lull

     

    http://bit.ly/YwwBOd

     

    >>After beginning work on a vaccine with Novartis ($NVS) and others last month, CDC now aims to have a product in clinical trials this summer, Frieden told Reuters. The timeline is dependent on how successful CDC is in its efforts to shave weeks off earlier pandemic vaccine programs. Medicago claimed to be ahead of the field this week, having used its plant-based system to bring an H7N9 candidate to the cusp of immunogenicity studies in animal models.<<

     

    Medicago press release:
    http://bit.ly/ZKnsil

     

    Medicago (MDCGF.PK)
    9 May 2013, 10:02 AM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    I agree, SMartin. Just fired up a new, small position in Novavax. (500 shares). I think the last time I owned NVAX was way back in 2009 or 2010, during the H1N1 run up.

     

    I might have bought a little more, but the recent April sale of 79,000 shares by Gary Evans, a director, gives me some concern.

     

    9 May 2013, 11:59 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    According to the Vickers Insider Prophets Report available through my Schwab account, Evans still holds 702,588 shares, and is the only insider who sold at the top last month (and only about 10% of his position). He is the only insider listed who has sold in the 2011-2013 time frame captured in the report. Most others have been buying and holding substantial positions for the past three years.
    9 May 2013, 12:21 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    SMartin: Thanks! Before I bought, I checked out the Insiders List, and institutional holders...impressive!

     

    May add another small block in a few days.
    9 May 2013, 01:13 PM Reply Like
  • robert.b.ferguson
    , contributor
    Comments (10802) | Send Message
     
    Even directors need to take profit once in awhile.
    20 May 2013, 02:53 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    Boy, did I screw up. I'm a director in two mutuals! No equity rights!
    20 May 2013, 08:12 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    My favorite biotech, Sangamo Biosciences (SGMO) beat estimates yesterday. I listened to the CC yesterday, and they seem to be making great progress with their HIV trials.

     

    Up around 9% today.

     

    Here's the scoop, plus a link to listen to the CC:

     

    http://bit.ly/175j44T

     

    Gotta figure a way to get more of this stock in my portfolio.
    9 May 2013, 02:21 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Thanks, Maya.

     

    I shall take a look at it.
    9 May 2013, 02:40 PM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    Novavax H7N9 VLP Influenza Vaccine Enters Animal Testing

     

    - Novavax H7N9 VLP vaccine produced, purified and entered into preclinical immunogenicity and efficacy studies in less than a month
    - Production of GMP H7N9 clinical trial materials underway

     

    "... completed purification of a lot of A/Anhui/1/13 H7N9 virus-like particle (VLP) vaccine and initiated animal immunogenicity and efficacy studies, including studies intended to evaluate protection against wild-type viral challenges. Novavax began work on the strain in early April ..."

     

    http://bit.ly/14a1F72

     

    HardToLove
    10 May 2013, 10:22 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    That is good news.

     

    I would still like to hear that they have the emergency approval blessing from CDC and FDA and are going into human trials:

     

    http://bit.ly/10zsWRL
    10 May 2013, 10:28 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    SMaturin: with their past success in the Mexico trials for the swine flue and subsequent successful trials of it, and the BARDA funding for just such as this, I suspect it won't take long ... well, relative to how long these FDA trials normally take.

     

    I especially liked the 28 days statement.

     

    HardToLove
    10 May 2013, 10:55 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    So, they made it to the ball field after all. Outstanding news. Thanks HTL, I got a smile from that one, bolder stride, head higher and then the stairs came up and I almost fell down them.
    10 May 2013, 11:33 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    SM it probably won't happen til after a few animals complete the test. Safety first....but then I expect it quickly & it probably won't be all that long.

     

    In fact, I will now add to my tiny position on any pull back, short of bad news.
    10 May 2013, 04:16 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    OK, I left the sidelines today and entered the NVAX game at $2.09 this afternoon.

     

    The chart looks propitious, especially the Williams %R mentioned recently (by HTL?), which touched 100, and the start of an upswing this week in a significantly oversold picture.
    10 May 2013, 04:41 PM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    SMaturin: That %R is Maya's - I'd never heard of it until long ago when he mentioned it to me.

     

    He'll tell you better than I though - it's not infallible and will sometimes begin to move up out of it's trench even when pps doesn't do much.

     

    I use it in conjunction with other stuff.

     

    MHO and HTH,
    HardToLove
    10 May 2013, 04:45 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    Given my first name is William, I do like this indicator. I like it because it sometimes is a leading indicator. This indicator, along with RSI, and assistance from friend John Loundsbury, allowed me to call the July market bottom in 2009 three days before Doug Kass famously did. Unfortunately, I was in Honduras at the time, and with the electricity being completely unreliable, I didn't take advantage of that call. Still drives me crazy to this day.

     

    After these years of trading, I have seen all too often that stocks seem to jump when both RSI and W % R bottom simultaneously. Ya gotta figure the algoputers are programed to react and go into buy mode due to these indicators bottoming, as much as any other indicators.

     

    I didn't write about W % R regarding Novavax, but did with LINE over in QC.

     

    Love that NVAX rallied. Of course...I don't have enough!

     

    One more thing about NVAX discussed in the above interview is that NVAX is considered a portfolio hedge if this new strain of bird flu goes pandemic; airports shut down, schools close, markets tumble...and vaccine makers rocket.

     

    Does anyone recall the manufacturer of face masks? I recall that stock surging as well as NVAX during the H1N1 scare.
    10 May 2013, 05:51 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » There is a list up in the concentrator header:
    masks/ disinfectants… (APT) (MMM) (CLX) (ECL) (PURE)
    12 May 2013, 05:28 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    WOW, I just got in from Florida and see that NVAX rallied to $2.25 on the news.

     

    ZGNX:
    mpax Labs, Inc. (NASDAQ: IPXL) and Zogenix (Nasdaq: ZGNX) are active as the FDA denied a petition to block generic forms of Endo Pharma's (Nasdaq: ENDP) Opana.
    News Provided by Acquire Media Corporation
    10 May 2013, 04:54 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    4:15 PM Today's decision by the FDA on Endo's (ENDP -5.3%) Opana ER puts to rest an aggressive campaign begun last October by the drug developer to keep generic versions off the market. In the end, the agency comes full circle, reiterating that the original formulation of Opana ER was not withdrawn for reasons of safety or effectiveness. Therefore, generic versions of the original formulation can continue to be approved and marketed. Following a brief resumption of trading just before the closing bell, the stock has since been halted a second time. [Healthcare, On the Move] Comment!
    11 May 2013, 03:22 AM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    6 Superstars For Your Biotech Portfolio: John McCamant

     

    Nice, concise interview. Novavax and Sangamo Biosciences are discussed:

     

    http://seekingalpha.co...
    10 May 2013, 05:38 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Thanks Maya. That's an interesting article.
    10 May 2013, 06:15 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Adam Furenstein with TheStreet comments on 4 stocks including ZGNX. He is negative on all 4.

     

    http://bit.ly/12nzQa2
    11 May 2013, 03:14 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    I find AF's opinions about as useful as a prostitute's moral outrage at adultry.
    11 May 2013, 11:21 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Might be bullish for ZGNX then. I have no idea who AF is by reputation or name. I have never been very good with names and as I get older I am not so good with faces any more either. I guess I will just have to go on smell in the future. LOL
    13 May 2013, 09:16 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    DG, AF writes on bio-techs at TheStreet.com sometimes he is very very good at predicting. Mostly he just follows the crowd and doesn't get behind something until "after the fact".

     

    He does attend many of the major conferences and rubs elbows with the right people. I just follow him out of curiosity. He does have criteria that he goes by....sorta like Cramer won't do penny stocks like AXPW.
    13 May 2013, 09:56 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    1:49 PM Vanda Pharmaceuticals (VNDA +1%) moves up after Jefferies raises its price target from $6 to $7, saying that a Tasimelteon filing is forthcoming. The firm notes that VNDA has plenty of cash to make it through potential Tasi approval, and it continues to develop market awareness and build pre-launch demand critical mass. [Healthcare, On the Move] Comment!
    11 May 2013, 03:27 AM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    I've got a short story-
    My dog was lethargic during his regular exam on Wednesday. The vet suspected something and took a blood test that was positive for Lyme disease. The vet prescribed Doxycycline, a 28 day supply of 2 caps every 12 hours . She phoned in the scrip to the pharmacy. I went to get my scrip and the pharmacist told me that she wanted to talk to me first.

     

    She said that there were several manufacturers of Doxycycline in the past but since Katrina there was only one. (I have no idea why) I said and then? She said the manufacturer had increased the price by a factor of ten since they were the only game in town. The price of my 96 caps would be $512.80.

     

    After I was revived she said that everyone has the same reaction. I told her that I had some amoxicillin back home and would give Wolf that instead. She said there was supposed to be a coupon available for Doxycycline and got on the internet for 10 minutes and printed one out.

     

    The upshot of the story is that Wolf got his Doxycycline for $38.00 instead of $512.80.

     

    This is real and first hand. What the heck is going on? SMaturin can you spread some knowledge on this? Is this "normal?"

     

    Windwood Trader
    11 May 2013, 04:51 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Katrina hit some pharmacy companies really hard in our area. The "closed door pharmacy" that serves my institution was flooded (in Far Rockaway) and out of commission for several weeks, and other providers had to take over their business. But that is not the same as manufacturers getting shut down.

     

    I do not know who was the manufacturer or supplier of doxycycline in the east coast area that got hit by Katrina, but there have been shortages of drugs at various times in recent years, for a range of reasons, some of it having to do with regulatory errors or issues or misplanning. Perhaps one of the East Coast ports where supplies came in was damaged by Katrina.

     

    For example, the FDA only permits so much manufacturing of certain controlled substances, and if demand should go up, there will be an induced shortage. This happened with Adderall last year. Many ADHD patients had to switch to other drugs because the FDA would not permit manufacturers to make enough to satisfy growing demand, and the supply ran out before the end of the year.

     

    Doxy is such a common generic drug I find it hard to believe there would not be mutliple worldwide suppliers. And it is normally quite cheap, especially if bought in third world countries where there are not the government subsidies and insurance systems that drive the price up here in the states.

     

    This is an example of supply and demand being distorted by govenrment interference in free markets. Doxcycycline should be relatively cheap and plentiful normally.

     

    The FDA lists four suppliers on their drug shortage reporting website: http://1.usa.gov/16pX3Oq

     

    Here is a discussion of your very problem from a dog journal. http://bit.ly/14dXN4Z
    11 May 2013, 06:04 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    Thanks, Doc-

     

    The amoxicillin I referred to before was prescribed for me as the result of a tick that required minor surgery to remove. The doctor on duty at the walk-in-clinic I went to said that it was a $4.00 scrip for cash but if I had insurance it would be a $36.00 scrip with a $5.00 co-pay. The pharmacist asked me which way I wanted to go. It was 01:30 and the CVS computers were down.

     

    Before I said anything the pharm just walked back and two minutes later came back and handed me a bottle of 48 and said have a good day- Didn't want to be involved with money at 1:30 in the morning I guess.

     

    I never needed much in the way of drugs but I sure can see why folks go over the borders to get them.

     

    As to the other link about the dogs- that is right on point! They only wanted to charge $6.00 a cap though.

     

    Windwood Trader
    11 May 2013, 06:58 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    SM-
    I would guess you're at either Penninsula or the old St. John's Episcopal. I provided the RNs medical benefits at both at one time or another. Did they ever merge?

     

    Windwood Trader
    11 May 2013, 07:07 PM Reply Like
  • DRich
    , contributor
    Comments (4557) | Send Message
     
    Medicine has gone beyond De-regulation and into Un-regulation.

     

    http://bit.ly/10E062E

     

    Medicare for All !
    11 May 2013, 05:42 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Gummint healthcare will be just fine for anyone who's not a clunker.

     

    We'll soon all be getting our mandatory colonoscopies at the DMV.
    11 May 2013, 07:10 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Before I retired from nursing, the same thing happened with SoluMedrol. Only two companies made it after it went generic. One of them closed, leaving a big shortage. Price skyrocketed.

     

    Companies really don't want to compete on cheap generics. If no money in it, they just don't make it and focus on one or two drugs they can squeeze a profit out of.
    11 May 2013, 07:33 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » WHO says new coronavirus may be passed person to person

     

    The World Health Organization says it appears likely that the novel coronavirus (NCoV) can be passed between people in close contact. "Of most concern... is the fact that the different clusters seen in multiple countries increasingly support the hypothesis that when there is close contact this novel coronavirus can transmit from person to person," the World Health Organization said on Sunday. http://tinyurl.com/cxw...
    12 May 2013, 03:58 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    This new coronavirus (nCoV) could be very bad, as well.

     

    We do not yet know what the animal reservoir may be, and it is clear that it spreads by human contact in the cases that have been imported from the gulf region.

     

    http://bit.ly/17ixmPS

     

    The mortality rate is over 50% in known cases so far: 20 of 33.
    12 May 2013, 05:00 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Is anyone working on a vaccine for this. Over 50% kill rate seems quite serious. Add this to the H7N9 and we could really reduce the world population in a one-two punch. Scary. Tin foil hats will not do well pondering on this to long. LOL
    13 May 2013, 09:30 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    DG,

     

    At this stage the authorities are in surveillance mode. I have not heard of any vaccine planning discussion:

     

    WHO:
    http://bit.ly/165FMdM
    http://bit.ly/19iBP1y

     

    CDC: http://1.usa.gov/165FKTa
    13 May 2013, 09:39 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Thanks SM, So the H7N9 might not be the one to worry about. Hmmmm.
    13 May 2013, 10:00 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Experts offer dim view of potential vaccine response to H7N9

     

    http://bit.ly/10QI7Ap

     

    >>
    May 10, 2013 (CIDRAP News) – If the H7N9 influenza virus now circulating in China evolves into a pandemic strain, the world is likely to have great difficulty providing adequate supplies of an effective vaccine in time to blunt its impact, according to a viewpoint article by three experts in the Journal of the American Medical Association (JAMA).

     

    "Even with additional vaccine manufacturing capacity . . . the global public health community remains woefully underprepared for an effective vaccine response to a pandemic," says the commentary by Michael T. Osterholm, PhD, MPH, and colleagues with the University of Minnesota's Center for Infectious Disease Research and Policy, which publishes CIDRAP News.

     

    The authors say an H7N9 vaccine may have limited effectiveness, given the performance of other H7 vaccines that have been tested. In addition, they say the vaccine might arrive too late to do very much good and that global vaccine production capacity may fall far short.

     

    Two other experts who were not involved in writing the commentary agreed with it in some respects but were less pessimistic about the ultimate impact of an H7N9 vaccine, if one is needed.
    <<

     

    ----------------

     

    >>
    Another flu expert, Arnold S. Monto, MD, an epidemiology professor at the University of Michigan, said he generally agrees with Osterholm and colleagues on a number of points, but he suggested that pandemic preparedness efforts in recent years have made a difference.

     

    "Granted, this is going to be a difficult one," he said. "But we have to view it against the alternative of what else we have right now. Fortunately, the work on H5N1 has left us in a much better position to respond to this than if we had not done that work. It's pretty clear we're going to need an adjuvant, and there's been a lot of work on adjuvants." (Adjuvants are vaccine additives that boost the immune response, making it possible to vaccinate more people with a given amount of antigen.)

     

    No adjuvanted flu vaccine has been licensed in the United States, but Monto said regulatory requirements should not be a big obstacle, because the Food and Drug Administration could issue an emergency use authorization.
    <<

     

    Novartis cell-culture based technology mentioned.
    12 May 2013, 04:47 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    The JAMA article is available online:

     

    http://bit.ly/123XTKw

     

    >>
    Data for seasonal influenza vaccines and the 2009 A(H1N1)pdm09 vaccines provide a basis for estimatingpotential effectiveness of A(H7N9) vaccines. Inactivated seasonal influenza vaccines have a pooled efficacy estimate of 59%, primarily for younger adults.4 A paucity of evidence exists for demonstrating protection in adults aged 65 years or older, particularly with influenza A vaccines. The pooled efficacy of live-attenuated influenza vaccines (LAIVs) is 83% in children aged 6 months to 7 years, but currently available data do not support effectiveness in the population aged 8 years or older.4

     

    The median effectiveness reported in 6 studies of adjuvanted A(H1N1)pdm09 pandemic vaccines was 72% (range, 60%-93%).4 In a study of unadjuvanted A(H1N1)pdm09 vaccine conducted in the United States, effectiveness was 56% (95% CI, 23%-75%).4 For these studies, most participants were younger than 50 years, with approximately half younger than 18 years.

     

    There is no reason to believe that a yet-to-be-developed pandemic A(H7N9) vaccine will perform any better than existing seasonal vaccines or the A(H1N1)pdm09 vaccines, particularly with regard to vaccine efficacy in persons older than 65 years. To date, the median age of H7N9 cases is 60 years. If a pandemic occurs and this epidemiologic pattern persists, a pandemic A(H7N9) vaccine, even if it includes an adjuvant, will likely have limited to modest effects on the overall morbidity and mortality from the novel strain.
    <<
    12 May 2013, 04:55 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    One of the references from the JAMA piece is relevant to this concentrator:

     

    Global production capacity of seasonal influenza vaccine in 2011
    http://bit.ly/12seyIl

     

    >>
    3.4. Current and future seasonal influenza vaccine production by WHO Region
    In 2011 there were 21 countries with seasonal trivalent influenza vaccine production capacity (Table 2). Production capacity was estimated as 691 million doses (48%) in the WHO European Region (EUR), 378 million doses (27%) in the Region of the Americas (AMR), 324 million doses (23%) in the Western Pacific Region (WPR), and 28 million doses (2%) in the South-East Asia Region (SEAR) (Fig. 1). In terms of actual production, EUR produced nearly 50% of the global supply of NH [northern hemisphere] vaccine followed by AMR, WPR and SEAR which produced 26%, 25% and <1% of global supply, respectively. For SH [southern hemisphere] vaccine, nearly 62% of global supply was produced in EUR followed by 33% in AMR and 5% in WPR. No seasonal trivalent influenza vaccine was produced in 2011 in the WHO Regions of Africa (AFR) or the Eastern Mediterranean (EMR); however, capacity is currently being developed in countries in these two regions along with additional countries in AMR, EUR, SEAR and WPR (Fig. 2).
    <<
    12 May 2013, 05:24 PM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    SMaturin: thanks for those two articles. My general knowledge is improving slowly in this area, which really is new to me.

     

    HardToLove
    12 May 2013, 05:12 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Interesting article about using adenovirus vector with influenza genes to immunize against H7N9. It could be a useful way to overcome the poor antigenic response to killed vaccine or VLP/proteins in H7 viruses:

     

    A New Vaccine To Protect Against Multiple Strains of H7N9 Bird Flu Virus
    http://bit.ly/12stF5L

     

    >>
    As a vector, Mittal used a safe adenovirus which could transport the flu virus genes into the body, which triggers a two-fold immune response of antibody and cell-based protection.

     

    The host cells infected with the adenovirus vector create influenza proteins that result in the development of antibodies and special T-cells prepared to destroy the virus and any infected cells.

     

    Any genes significant to protection against the avian influenza virus can be included inside the adenovirus vector - which can be made to expose the immune system to the surface as well as the internal components of the virus.

     

    "In this way the immune system can be primed to recognize portions of the virus that predominately remain the same across all strains and those that are more difficult for the virus to change as it adapts to the immune system attack," Mital said.
    <<
    14 May 2013, 02:09 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Good find SM, thanks.
    14 May 2013, 03:41 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Cutting edge biomolecular engineering:

     

    Synthetic Biology Could Speed Flu Vaccine Production

     

    http://bit.ly/16ysGp4

     

    >>
    At a meeting on synthetic biology held at MIT, the drug company Novartis said it has synthesized hybrid flu genomes in a process that could shave weeks off the time required to produce vaccines. When new flu strain emerges, government agencies normally send samples to vaccine manufacturers, who grow large numbers of the pathogen in chicken eggs as starting material for vaccines, says Philip Dormitzer, leader of viral vaccine research for Novartis. This process can take months and can miss the peak of an outbreak. But Novartis, working with synthetic biologists, has developed a way of chemically synthesizing virus genomes and growing them in tissue culture cells. That saves time and may produce more effective vaccines.

     

    The idea is to build a synthetic virus based on sequence data that can be distributed much more quickly than actual viral material harvested at the site of an outbreak. The synthetic viral genome combines a genomic backbone common to many flu viruses with genes specific to the strains seen in a new outbreak. In 2011, the team tested its method in response to a mock outbreak of a bird-flu virus (one closely related to the H7N9 virus currently spreading in China). Starting at 8 a.m. on Monday that year, the team began to chemically synthesize a viral genome based on sequence data, says Dormitzer. By noon the following Friday, the team had confirmed that it had live virus growing in cell culture.
    <<
    14 May 2013, 10:52 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    New Myeloma drug combo effective, mentions 3 companies moving forward in cancer tx.

     

    http://bloom.bg/10ZsnLl
    16 May 2013, 07:44 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Bloomberg.com has an article out on the healthcare workers getting the new SARS type virus, now street named Middle East virus.

     

    Death rate running about 50%. They are keeping this hush hush. But it has spread to several countries now.

     

    NVAX down, anyone have any comments ?

     

    ZGNX selling off probably ahead of the FDA denial of Zohydro.
    16 May 2013, 08:20 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    LT: (NVAX) down, IMO, because those investors that did the financing got the price up where it became profitable for them to exit as folks got sucked in on the story. Those that have been around this stock for a while know that the H7N9 news is transient and wont result in any near-term change in company position, no likely fast-tracking, etc.

     

    If I've got that right, reversion to trend is a natural result.

     

    MHO,
    HardToLove
    16 May 2013, 08:33 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    so how low does your magic think it will go ?
    16 May 2013, 09:16 AM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    LT: In addition to what HTL wrote, which I believe to have cred...

     

    For the record, yesterday I sold my miniscule amount of NVAX for basically a wash from the commissions of buying and selling. The charts say to get back in around $1.80, as support. I may fire up another miniscule position down there.

     

    However....

     

    There was another catalyst for the stock to retrace as yesterday, somewhere in China (several provinces or states or whatever they call them over there), I read that this new strain of bird flu had been taken off the pandemic rating...that's when I sold.
    16 May 2013, 09:52 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    thx Maya, I expected that as the chatter has died down since the other global scientists went over there.

     

    Looks like the Mid East SARS is taking it's place tho. Much more deadly
    16 May 2013, 10:18 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17774) | Send Message
     
    LT: unsure ATM - got to get through options expiration wee dontcha know! :-))

     

    So far, I've been not pulling the trigger though because an (unreliable) gut hunch is thinking somewhere below $2 again.

     

    HardToLove
    16 May 2013, 12:14 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Who else is watching Novabay (NBY)?

     

    I have been watching from the sidelines for months now. W%R just hit 100 again. In the past it has bounced a bit and then taken off for awhile.

     

    It has a promising technology that may have phase IIb results by the end of the year: http://bit.ly/YYL7k9

     

    Pipeline: http://bit.ly/10AKyam
    16 May 2013, 11:11 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Boston Scientific could be a low risk play:

     

    http://bit.ly/10bcV3t
    18 May 2013, 07:47 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    another case of the mid-east SARS, they are keeping this quiet for some reason.

     

    http://yhoo.it/13DTUre
    19 May 2013, 07:10 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » They need to come to a consensus on the severity of the threat ASAP because Ramadan is approaching. Ramadan draws roughly three million Muslims from around the world every year to the Hajj, a mass pilgrimage Muslims are meant to perform at least once in their lifetimes. Nearly one million international tourists travel to Mecca during Ramadan - Close proximity. Ramadan is expected to begin on or around July 9 and will finish on or around August 7 this year.
    19 May 2013, 10:02 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Holly Crap Rattie, That could certainly lead to spreading this and creating the pandemic everyone fears. Good point!!!
    20 May 2013, 11:20 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Shuttlecocks to cost more due to H7N9
    By Ou Hailin (China Daily)
    11:18, May 17, 2013
    Feather market in 'chaos' as concerns over bird flu affect supply, production

     

    Bad news for badminton fans: The price of shuttlecocks will rise in coming months as the supply of duck feathers needed to make them dwindles because of the H7N9 bird flu outbreak.

     

    "We're planning an increase of 4 or 5 yuan (65 to 81 US cents) for each pack of 12 shuttlecocks in July, if bird flu has not been brought under control by then," said Liu Zhisong, a technical manager at Bo'er Shuttlecock Factory, one of the largest shuttlecock manufacturers in Anhui province.

     

    .......

     

    "The feather market is in total chaos," said Li Min, whose business focuses on supplying processed feathers to shuttlecock producers. "In just 20 days after the outbreak of H7N9, the price of natural duck feathers increased by about 40 percent. And even with the high price, it's hard to get them right now."

     

    http://bit.ly/Z5tuPA

     

    The inexorable laws of supply and demand threaten the noble game...
    "Usually, most shuttlecock producers would keep a two-month storage of feathers," Jin said. "But if H7N9 continues and governments' restrictions on trade in the live poultry market do not end, not only the price will shoot up, the shuttlecock industry itself will be in peril."
    19 May 2013, 10:44 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Threatwatch: Could a MERS vaccine make people sicker?

     

    http://bit.ly/12EzkFU

     

    >>
    Last year Robert Couch of Baylor College tested four experimental SARS vaccines in mice. All the vaccinated animals resisted infection, yet exposure to the SARS virus led to a severe lung inflammation similar to that seen with the RSV vaccine. The same thing, he reported, has been seen with many other experimental SARS vaccines.

     

    The problem seems to be that rather than aiding the destruction of the invading virus, the antibodies switch sides. Malik Peiris of the University of Hong Kong found that antibodies to a vaccine made from the main surface protein of SARS allow the virus to enter immune cells, where they can trigger a destructive immune attack on the lung.
    <<
    19 May 2013, 11:02 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    I am looking at Cempra (CEMP) for a very promising new antibiotic currently in Phase III.

     

    http://bit.ly/14ohVlw

     

    Company website about solithromycin: http://bit.ly/10IRAOt
    20 May 2013, 11:33 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    chronic inflammatory diseases, endocrine diseases and gastric motility disorders.

     

    SM, OK possibly a little education needed. I am assuming this is for respiratory and digestive (lungs and gut, real basic terms) infections. Yes/No?
    20 May 2013, 11:55 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Solithromycin is a fourth generation macrolide antibiotic. This family of drugs began with erythromycin, an old standby. Over the years, other drugs in the chemical class with the same mechanism of action have been developed, notably clarithromycin and azithromycin (the Zithromax Z-pack). They act via inhibition of bacterial ribosomes.
    http://bit.ly/115aAII

     

    Of particular interest with "soli," compared to older macrolides, is that it appears to act at three separate receptors on the bacterial ribosome, compared to only one or two sites for older drugs. This is believed to reduce the likelihood of bugs developing antibiotic resistance to soli, since it would require three spontaneous mutations for different receptor proteins all at the same time, to knock out all three sites of action. Big potential plus, as there are azithromycin-resistant strains in the wild.

     

    Another big plus, macrolides appear to have anti-inflammatory activity independent of their antibacterial activity, by inhibiting neutrophil migration into sites of inflammation, particularly in the lungs. Soli has more of this activity, as measured in vitro, than previous macrolides. http://bit.ly/10Q5NGq

     

    This is a bonus in Chronic Obstructive Pulmonary Disease, as well as in Cystic Fibrosis, both of which have a component of chronic lung inflammation as a pathological process. Studies of chronic administration of azithromycin in cystic fibrosis patients have demonstrated improved lung function over time. The downside to giving a macrolide for months or years to CF patients is the increased risk of developing community strains of resistant bacteria. See paragraph two, above.

     

    Soli looks to be a very promising addition to the family, that is more than just a me-too drug. It actually will have some therapeutic advantages over older macrolides that are now generic. The current Phase III trial in community acquired pneumonia is due to finish in April 2014. All trial data to date have been very encouraging.

     

    There is also a phase II trial underway using a one-dose oral treatment with Soli for gonorrhea. Another excellent market, as community strains have developed resistance to many other antibiotics. A single shot in the butt of penicillin is no longer the best choice there.
    20 May 2013, 12:17 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Thanks SM, very pertinent & informative info.
    20 May 2013, 12:22 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Hmmmm There is also a phase II trial underway using a one-dose oral treatment with Soli for gonorrhea. Another excellent market, as community strains have developed resistance to many other antibiotics. A single shot in the butt of penicillin is no longer the best choice there.

     

    I guess that will help here.

     

    http://huff.to/18YRg1z
    20 May 2013, 12:23 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Fascinating perspective on regulatory overreach by the FDA:

     

    http://bit.ly/18ZGEQ9

     

    Is it being regulated as a food or as a drug?
    20 May 2013, 06:15 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    MERS is spreading from trips to Holy Mecca:

     

    http://bbc.in/119ceTP

     

    http://bit.ly/16K3c8T

     

    http://on.wsj.com/17Z81uB

     

    While the lawyers diddle:

     

    http://bit.ly/119chyQ

     

    http://bit.ly/12rRLMn
    21 May 2013, 12:06 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » Unbelievable…
    21 May 2013, 02:14 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    As MERS spreads, frustration at lack of info grows

     

    http://bit.ly/12uA5jg

     

    >>
    "Let's hope this bug doesn't make it to Mecca." The bug in question is MERS, the coronavirus that emerged last year in the Arabian Peninsula.

     

    Ron Fouchier of Erasmus Medical Center in Rotterdam, the Netherlands, has good reason to be concerned. The virus is so far known to have infected more than 40 people, some of whom haven't apparently been in contact with an infected person or potentially infected animal.

     

    In an epidemiological analysis, the World Health Organization concludes that this means there could be many mild, unrecognised cases spreading the virus in the general population. "The continued appearance of cases that are not part of larger clusters, and who do not have a history of animal contact, increases concerns about possible community transmission," they report.
    <<

     

    This could get Biblical.
    22 May 2013, 10:35 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    You mean Quran, sorry I could not help myself. Still working on going to far.
    22 May 2013, 11:16 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Events in the Middle East that have recurred for millenia:

     

    Jeremiah 28:8 The prophets that have been before me and before thee of old prophesied both against many countries, and against great kingdoms, of war, and of evil, and of pestilence.

     

    http://bit.ly/16ORZE1
    22 May 2013, 11:47 AM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    It may be here in Alabama already. Not sure yet.

     

    http://bit.ly/10TEJ95
    22 May 2013, 11:11 AM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >DG-

     

    Sounds a little like Legionnaire’s Disease. I had a related form of that in the late 80's- Bacterial pneumonia they believe I acquired from mouse dirt while working in an attic, not from ductwork. I was uncatalogued but that's what they settled on.

     

    WT
    22 May 2013, 08:33 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    Are you sure that was not the hantavirus? Its about 75% fatal however so maybe it was not but it comes from rodent urine.

     

    http://bit.ly/14lqpuB

     

    Sorry so late just back from hunt in Alberta Canada.
    7 Jun 2013, 10:18 AM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >DG

     

    It might well have been hantavirus. When admitted, my liver and kidneys all shut down and my blood was toxic. Not quite sure what toxic blood means but a guy in a black outfit and a reversed collar insisted on giving me the Last Rites. I was too weak to argue.

     

    I had both arms and legs with push feed IVs shooting industrial Raid into my body to kill the bugs and whatever else IVs do. My doc told me to have courage. Sheesh!

     

    Six days later I got rolled to a car and not the one way limousine ride.

     

    WT
    7 Jun 2013, 05:13 PM Reply Like
  • doubleguns
    , contributor
    Comments (8199) | Send Message
     
    What ever it was I am glad you pulled through.

     

    We had to worry about that virus in Yuma Arizona when I was stationed there. That is where I found out about that virus.

     

    Yosemite last year had to inform a bunch of folks that they may have been exposed to that virus.

     

    http://1.usa.gov/18cU79a
    7 Jun 2013, 05:48 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » H7N9 bird flu found to spread through the air

     

    The H7N9 bird flu virus can be transmitted not only through close contact but by airborne exposure, a team at the University of Hong Kong found after extensive laboratory experiments.

     

    Though the virus appears to have been brought under control recently, the researchers urged the Hong Kong authorities to maintain strict surveillance, which should include not only poultry but humans and pigs.

     

    "We also found that the virus can infect pigs, which was not previously known," said Dr Maria Zhu Huachen, a research assistant professor at HKU's School of Public Health.

     

    In the study, to be published today in the journal Science, ferrets were used to evaluate the infectivity of H7N9. It was found the virus could spread through the air, from one cage to another, albeit less efficiently.

     

    On a more positive note, it was found that the virus is relatively mild.
    "Most of the fatal H7N9 cases had underlying medical conditions, so there are probably some other factors that contribute to this kind of fatality," Zhu said. http://tinyurl.com/ns2...
    23 May 2013, 09:43 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    They probably found this out with the international team that visited and it's now being made public.
    The other underlying causes are present in many many cases. The acuity level of people in hospitals is much much higher than 20 years ago, so most patients will have underlying med. conditions.

     

    I would not be so sure that it is "less harmful" than earlier.
    23 May 2013, 09:49 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Today's entertainment on the H7N9 front:

     

    UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine
    http://bit.ly/18oeBbG

     

    Expect to see this in your next SkyMall catalog.
    24 May 2013, 01:09 PM Reply Like
  • WDD
    , contributor
    Comments (60) | Send Message
     
    Not to be confused with UV-C germicidal bulbs, which will indeed disrupt microscopic nasties, but will also burn your retinas and epidermis.

     

    How long before someone sees that photo and decides to stick their SteriPEN water purifier up their nose?
    24 May 2013, 04:43 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM-

     

    Pretty close- Just have to wait for the next edition.

     

    http://bit.ly/1bhThnW
    8 Jun 2013, 05:04 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    And on the MERS front:

     

    Saudis say Dutch patent on MERS virus hampers research
    http://bit.ly/Z5ss46
    24 May 2013, 01:17 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    I wait with bated breath for the announcement of nano-machine's capability to be injected into the bloodstream carrying all sorts of devices to not only attack virus and bacteria neutralizing it to be removed by the normal bodily functions but to also carve plaque from the walls of blood vessels and repair damaged cell structures.

     

    My only regret is that they will be likely owned and controlled by the oil companies and the fat cats.

     

    WT
    27 May 2013, 09:43 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    WT, that would be a great step to help mankind. Helping people is not a part of capitalism. Profit only. Just think at Medicare and insurance savings with basically no stents and open heart surgeries.

     

    at $75,000 a pop, it racks up dollars.
    27 May 2013, 10:16 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    2:48 AM AstraZeneca (AZN) has agreed to acquire Omthera Pharmaceuticals (OMTH) for up to $443M as the U.K. company carries out its strategy of building up its cardiovascular drug business. The price includes an upfront payment of $323M, or $12.70 a share, which represents an 88% premium to Omthera's close on Friday. AstraZeneca will pay another $120M based on the success of Omthera's experimental drug Epanova for treating very high levels of triglycerides, a fat found in the blood. (PR) Comment! [Healthcare, M&A]
    28 May 2013, 03:14 AM Reply Like
  • robert.b.ferguson
    , contributor
    Comments (10802) | Send Message
     
    Indeed! The death panels are coming under Obamatax. http://bit.ly/ZLF6HS
    4 Jun 2013, 01:55 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    BDSI looks promising,
    http://seekingalpha.co...
    28 May 2013, 08:18 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    CHAPEL HILL, N.C., May 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Cempra with a five year contract valued up to $58 million for the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens. Solithromycin, Cempra's lead product candidate, is a fourth generation macrolide antibiotic in the fluoroketolide family that is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. The company will host a conference call and webcast at 8:30 a.m. EDT, tomorrow, May 29, to discuss the agreement.
    28 May 2013, 09:50 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Now I'm kicking myself for putting in a bottom-feeder low bid last week on (CEMP).
    28 May 2013, 03:39 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM-

     

    (CEMP) Pretty shaky looking right now- Do you see an opportunity?
    4 Jun 2013, 02:44 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    WT,

     

    I am waiting for it to retrench under $7: http://scharts.co/ZLPfEA

     

    Solithromycin will be the first of the "fourth generation" macrolide antibiotics, with excellent broad-spectrum coverage of resistant organisms, as well as more inherent anti-inflammatory pharmacologic effects than any previous macrolides. (See my 20 May comment above).

     

    It will be volatile heading into the "sell in May and go away" season, but the phase three trial results will make it pop again later this year. Today is just profit-taking from the last pop on minor good news last week.

     

    This is one to bottom feed for the sock drawer in the coming months.
    4 Jun 2013, 03:09 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM-

     

    Thanks for the heads-up. I love the sock drawer analogy. It seems that most of what I have left is in the "wait until this mess resolves itself" category.
    4 Jun 2013, 06:45 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    (CEMP) did its retrenchment today after announcing yesterday after the bell (4:01 PM) that they would do a public offering to fund the next Phase III trial. http://bit.ly/11F43QI

     

    At 4:02 PM they explained why this was a positive: http://bit.ly/11F446Y

     

    >>"We believe our End-of-Phase 2 meeting with the FDA has provided us with clear direction toward approval of solithromycin for CABP [community-acquired bacterial pneumonia]," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. "We were pleased with the FDA input and believe we are in a position to proceed with our second Phase 3 study and the rest of the clinical program, subject to receipt of the necessary funding. We know the requirements for the CABP safety database and efficacy endpoints for NDA submission. In addition, we received preliminary feedback on the trial design for the uncomplicated gonococcal infection indication."<<

     

    This morning they announced the offering will be at $7.00:
    http://bit.ly/11F4470

     

    I see it as good news that they are on track with FDA to get solithromycin to market in a couple of years.

     

    See my earlier discussion for the reason this should be a great drug: http://seekingalpha.co...

     

    I have opened a position at $7.28 this morning.
    14 Jun 2013, 10:24 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Cempra insider ownership: 35% according to Reuters info this week.

     

    Trading Date Name Title Type Shares Traded Price
    16 Aug 2012
    MORRIS WISTAR I III

     

    Beneficial Owner of More than 10% Class Buy 2,500 $7.62
    7 Feb 2012
    NEFF P SHERRILL

     

    Director and Beneficial Owner Buy 1,189,805 $6.00
    7 Feb 2012
    INTERSOUTH ASSOCIATES VI L L C

     

    Beneficial Owner of More than 10% Class Buy 488,659 $6.00
    7 Feb 2012
    INTERSOUTH ASSOCIATES VI L L C

     

    Beneficial Owner of More than 10% Class Buy 732,989 $6.00
    6 Feb 2012
    AISLING CAPITAL II L P

     

    Beneficial Owner of More than 10% Class Buy 1,213,663 $6.00
    6 Feb 2012
    AISLING CAPITAL II L P

     

    Beneficial Owner of More than 10% Class Buy 1,213,663 $6.00
    6 Feb 2012
    GOLDSTEIN DOV A

     

    Director Buy 1,213,663 $6.00
    6 Feb 2012
    AISLING CAPITAL II L P

     

    Beneficial Owner of More than 10% Class Buy 1,213,663 $6.0
     
    Company insiders current positions: 
     
    MORRIS WISTAR I III
    Trading Date Type Shares Traded Price Shares Held
    16 Aug 2012 Buy 2,500 $7.62 2,233,001
     
    NEFF P SHERRILL
    Trading Date Type Shares Traded Price Shares Held
    7 Feb 2012 Buy 1,189,805 $6.00 3,262,154
     
    GOLDSTEIN DOV A
    Trading Date Type Shares Traded Price Shares Held
    6 Feb 2012 Buy 1,213,663 $6.00 3,293,060
     
    8788215 total insider shares of 24900000 os = 35% ownership on board
     
    14 Jun 2013, 01:10 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    I have expected to hear this soon, as I have stated Tamiflu effectiveness is limited if at all.
    This could be an opportunity in NVAX, BCRX, and couple of other bird flu prospects listed in this APC.

     

    New Bird-Flu RESISTANT to Roche's Tamiflu.
    http://bloom.bg/11mLSO7
    28 May 2013, 10:02 AM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    With the above report, reported by LT about Tamiflu dosages "spurring a mutation," of H7N9, it seems that the runaway benefactor is Sanofi Biosciences (SVA), which is up a whopping 20.54% today, with 2.5 times normal volume.

     

    NVAX remains unaffected, and is down two cents.
    28 May 2013, 03:49 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9832) | Send Message
     
    Adding, the Q-report came out today about SVA:

     

    Sinovac Biotech (SVA): Q1 EPS of -$0.04 beats by $0.06. Revenue of $10.1M misses by $0.19M. (PR)
    Tuesday, May 28, 7:17 AM ET
    28 May 2013, 03:57 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    thx Maya, SVA is the one I couldn't find
    28 May 2013, 05:27 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Novavax, Inc. (NASDAQ: NVAX) made a public tender offer to acquire all outstanding shares and warrants of Sweden-based Isconova AB (NASDAQ OMX First North Premier: ISCO) directly from such holders and intends to make a private offer for all outstanding stock options. The total transaction is valued at approximately $29.6 million USD based on the June 3, 2013 closing stock price of Novavax's common stock. The offer has been recommended by Isconova AB's board of directors in a press release that was issued earlier this morning.
    Novavax will acquire all outstanding Isconova AB shares for approximately 15.5 million shares of Novavax common stock, corresponding to an offer value of SEK 15.46 for each Isconova share. In addition, Novavax has offered to cash out all outstanding 2005-I warrants and 2005-II warrants for SEK 140,277, based on a "Black-Scholes" valuation. Pursuant to the private offer for stock options, Novavax intends to issue 218,120 shares of Novavax common stock, corresponding to a value of SEK 8.30 for each option share.
    News Provided by Acquire Media Corporation
    4 Jun 2013, 08:22 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » (NVAX)
    Here is a blurb on the acquired company Isconova:

     

    Isconova AB is a leading international vaccine adjuvant company.
    The company has extensive knowledge of vaccine systems
    and develops vaccines based on the Matrix technology
    together with partners in the human and veterinary markets.

     

    Isconova’s main focus is in human vaccines, (Pipeline: two phase I studies
    completed, three phase I studies ongoing) fuelled by the growth profile
    of the human vaccine market ($57,6B by 2015 globally http://tinyurl.com/mo5... ).

     

    From todays 8K: Nvax believes that having full access to Isconova’s adjuvant program, along with the scientific and clinical teams that have been developing the technology for many years, will allow it to better understand, characterize and refine many of its vaccine targets, which can potentially lead to better, more potent vaccine candidates brought into clinical trials and eventually to market in less time.

     

    Check out the download on this page:
    http://tinyurl.com/mex...
    ---

     

    I think this is a very interesting development given the recent adjuvant issues associated with vaccines.

     

    This might be a counter play to VICL's Vaxfectin Adjuvant. This allows NVAX to complete with VICL and others in the Adjuvant line of business.

     

    It also might also be a "risk reduction" play with respect to our recent discussion of the potential danger of using Squalene as an adjuvant.

     

    This comment is from the SF concentrator on 3 March discussing NVAX's conference call:

     

    "I argue that the key point is whether ANY of their current products/ trials have exposure to Squalene.... Given the current negative attention directed at Squalene, I think it would be quite risky to use it for any new products/ trials and existing products until it's given a clean bill of health. So by not providing a denial on current Squalene exposure for all their products, risk exposure will remain unknown for shareholders. That potential risk exposure issue could have been buried if Dr. Fries had been able to provide a denial.

     

    The Squalene issue raises experimental design issues for ALL manufacturers running trials of products designated to use Squalene, not just NVAX. For example, I doubt a manufacturer would be able to proceed on an advanced multi-stage trial if they were forced to change one of the ingredients in use during previous stages." http://seekingalpha.co...

     

    * Given this acquisition, I wonder if NVAX was using Isconova’s adjuvant all along. This acquisition also might explain Dr. Fries mysterious refusal to identify the adjuvant NVAX was using for its adjuvant. If they had brought the issue up, that could have thrown a monkey wrench into delicate acquisition negotiations with Isconova.

     

    It looks like the recent viral threats are giving traditional vaccine manufacturers production difficulties requiring the use of safe Adjuvant's to stretch the vaccines. So this acquisition might be expected to open up a new revenue stream allowing NVAX to sell Adjuvant's to traditional manufacturers.

     

    NVAXs share price dropped 5.3% on the news no doubt because the acquisition involves the issuing of 15.7M of new shares to fund the acquisition. This is about 10.3% of issued and outstanding shares and therefore represents a substantial dilution.

     

    My reading of the tea leaves:
    I like the deal from a strategic standpoint. The question for me concerns finances for the joint company. Here is a quick look at Isconova’s year over year financial performance: http://tinyurl.com/kkg...

     

    Those results suggest why Isconova was looking to be acquired. My concern is that neither company is currently profitable, and the acquisition increases the net burn rate for (NVAX).

     

    Timing?
    Why an acquisition at this time? If NVAX is currently using Isconova's adjuvant's, and if Isconova is having financial difficulties, was the acquisition a defensive move designed to basically block NVAX rivals from acquiring technology that NVAX needs for it's product developments.

     

    Right now I read this as a near term defensive play with a long term strategic positive. As a result, I expect NVAX's stock price to drop near term. It should drop because when the companies join, I would think the bleed rate would increase. Therefore, I am looking to start accumulating around 1.25 to 1.30. If it does not drop than something else is probably up...

     

    What do you guys think?
    4 Jun 2013, 10:33 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    FPA. I think you pretty well summed it up, I would add that soon after this is all done or approved NVAX does a capital raise to assure development...that's when the stock probably bottoms.

     

    thanks for the dig into this.
    5 Jun 2013, 04:00 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Cytokinetics had good news in the PR today, yet the price dropped 7% in the downdrafting market. http://on.wsj.com/15EGv22

     

    See my comment here: http://bit.ly/ZLS0pi

     

    CYTK is another early stage biotech with some revolutionary compounds for treating neuromuscular diseases. Sock drawer material as the clinical trials play out.
    4 Jun 2013, 03:20 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM-

     

    Is that being tried on fibromyalgia at this time? I know there was talk of a breakthrough very recently with work done at Albany Medical College.
    8 Jun 2013, 11:48 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    "Fibromyalgia" is a different can of worms entirely from genuine neuromuscular diseases.

     

    http://bit.ly/11zfA7h

     

    The exact definition of fibromyalgia as a specific physiologic disorder remains elusive and contentious. My view is that it is primarily supratentorial.
    8 Jun 2013, 12:17 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM-

     

    Thanks for the link.
    I think a lot of those apparently afflicted may just be afflicted by the images in their own minds along with their afflictions-

     

    PTSD thought to be a possibly related cause. Hmm.

     

    Here's a link to the article.

     

    http://bit.ly/14orUZ3

     

    WT
    8 Jun 2013, 04:50 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    NVAX big news :

     

    Novavax, Inc. (NASDAQ: NVAX) said it had successfully produced a vaccine candidate designed to provide protection against the recently emerging Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The vaccine candidate, which was made using Novavax' recombinant nanoparticle vaccine technology, is based on the major surface spike (S) protein. The Company believes that its MERS-CoV vaccine candidate may provide a path forward for a vaccine for this emerging threat.
    News Provided by Acquire Media Corporation
    6 Jun 2013, 07:13 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    10:06 AM Isis Pharmaceuticals (ISIS +1.8%) has earned a $6M payment from AstraZeneca (AZN +0.8%) as part of their partnership to develop antisense therapeutics to treat cancer. In the six months since the collaboration was announced, Isis and AztraZeneca have decided to develop the ISIS-ARRx compound for use in treating prostate cancer, and initiated two clinical studies for ISIS-STAT3Rx in patients with advanced lymphomas and liver cancer. (previous) (PR) [Healthcare] Comment!
    6 Jun 2013, 10:43 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    I am putting AtheroNova (AHRO.OB) on my radar list this week.

     

    I saw it mentioned as a spec yesterday here: http://bit.ly/11HmUt0

     

    Trying to figure out what their magical new chemical is, AHRO-001, I have decided it is hyodeoxycholic acid: http://bit.ly/11nk8Kt

     

    The company has patented it: http://bit.ly/ZSq43a

     

    Here is the preclinical work that makes this look promising as a hyperlipidemia treatment to manage atherosclerosis:

     

    http://bit.ly/ZSn5Ys

     

    http://bit.ly/ZSn8Du

     

    When they have some human data showing that ingesting this bile salt derivative is well-tolerated, this could turn out to be extremely promising, cutting into the statin and fish oil markets, or being used in combo with them.

     

    Looks like human studies have started in Russia: http://bit.ly/ZSqCGa

     

    PS: the Vickers Insiders report shows good insider buying profile in this penny stock.
    6 Jun 2013, 12:21 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    I created a Google News page for this, using search terms "AtheroNova, AHRO-001, hyodeoxycholic acid"

     

    Here is a useful recent article I missed earlier, which came up under the news search for "hyodeoxycholic acid:"
    http://bit.ly/13qaYjH
    7 Jun 2013, 01:02 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    More on AtheroNova:

     

    Combining Therapies to Amplify the Effects of Statins
    http://bit.ly/1bwkTWk

     

    >>It also highlights unique juniors in the space like AtheroNova Inc. (OTCBB: AHRO) and what they have to offer as a stand-alone therapy or complement to statins with their research in regressing atherosclerotic plaque and improving lipid profiles. The rubber is about to meet the road for AtheroNova as its licensing partner, CardioNova, has recently received protocol approval from the Russian Ministry of Healthcare, meaning that a Phase I trial of AHRO-001 should be commencing in the near term. AtheroNova’s press release from May 30th states that the drug product has been shipped to CardioNova, representing the last major step prior to initiation of the trial. The first patient dosing is expected in mid-to-late June.
    AHRO-001 is a novel drug candidate that utilizes naturally occurring compounds for the process of delipidization to dissolve plaque that forms in artery walls. AtheroNova’s compound has been shown in laboratory research to dissolve plaque deposits into molecules small enough to pass through the arterial fibrous cap where it can be then be removed by the body through natural processes.
    The power of statins is well documented to not only lower LDL levels, but also provide other benefits of potential plaque reversal and demonstrating an atheroprotective effect. They are also shown to modestly improve HDL, or “good” cholesterol, levels and reducing the size of arterial plaque to a small extent.
    AtheroNova believes that the mechanism of actions in AHRO-001 not only deliver similar LDL lowering results as statins, but also are involved in emulsifying plaque, upregulating ABCA1/ABCG1 gene expression, decreasing cholesterol absorption, stimulating reverse cholesterol transport and boosting HDL efficiency to a higher degree.<<
    12 Jun 2013, 12:57 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM
    I have Google News access but could not pull in the page. Have not tried to with anything else either so I'm pretty sure it's the nut on the keyboard-

     

    Any hints?
    14 Jun 2013, 09:47 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    The 7 Jun post is an article titled "Finding the Next Big Blockbuster Drug. Published Thursday, May 16, 2013 by Justin Kuepper" on a site called SECfilings.com.

     

    The 12 Jun post is titled as posted above, on a site called StockHouse.com.
    14 Jun 2013, 10:31 PM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    AtheroNova announced its Phase I study today:

     

    http://bit.ly/17bfV1l
    25 Jun 2013, 11:05 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    AHRO announced the publication of the preclinical results:

     

    http://bit.ly/1cqghBA
    27 Jun 2013, 09:17 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Who Owns MERS?

     

    http://fam.ag/195qt5j

     

    The story of how govt officials interfere with scientific progress.

     

    Are the Dutch "biopirates" or concerned scientists?
    7 Jun 2013, 09:28 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    7:47 AM BioDelivery Sciences (BDSI) says a pre-NDA meeting with the FDA regarding its Suboxone competitor BUNAVAIL went well, reinforcing expectations of an NDA filing by mid-summer. If approved, BUNAVAIL could capture ~$250M of what is quickly becoming a multibillion dollar market annually. SA contributor Scott Matusow likes the company's prospects, calling its market cap "way too low." (PR) [Healthcare] Comment!
    10 Jun 2013, 08:17 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Novavax, Inc. (NASDAQ: NVAX) Director James Young disclosed the purchase of 100,000 shares on 6/06 at $1.91, bringing his stake to 400,000 shares.
    Young has a history of good timing buying the stock. He bought 200,000 shares on December 2011 at $1.46. Shares nearly doubled, only to give back much of the gains.
    News Provided by Acquire Media Corporation
    10 Jun 2013, 09:20 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Good article on NVAX & it's pipeline

     

    http://seekingalpha.co...
    10 Jun 2013, 02:11 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    WHO says MERS has potential to be epidemic

     

    http://reut.rs/191bOW9
    10 Jun 2013, 08:36 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    (CYTK) up $.19 pre-market on joint venture deal w/Amgen-

     

    http://bit.ly/11VMdYz

     

    WT
    12 Jun 2013, 08:36 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Insider buying on NVAX & SANW ... nvax not significant but SANW is 13% owned by insiders which I find interesting.

     

    http://bit.ly/17JdcyT
    13 Jun 2013, 06:54 AM Reply Like
  • SMaturin
    , contributor
    Comments (2275) | Send Message
     
    Opened a position in NovaBay (NBY) today as it dropped to 1.30.

     

    I've been following this one for months and think the aganocide technology will turn out to be very useful and lucrative. Another sock drawer biotech that should do well with clinical results later this year.

     

    http://seekingalpha.co...
    18 Jun 2013, 11:14 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >SM-

     

    Added to (NBY) today by 2K shares. ASK was $1.25- Didn't get a hit. Finally went to a Market order by doing a $1.30 Limit.
    The 2K was spread evenly up the ladder from $1.26 through $1.29.

     

    Nobody's in the mood to sell- very thin trading.
    27 Jun 2013, 11:05 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » Thanks Doc. I added a large trading block to my current position in (VICL) today.

     

    The stock was initiated at Brinson Patrick with an Outperform. Brinson Patrick says Allovectin is poised to be a significant value driver for the company. They believe the results will be positive, which will position VICL with a blockbuster opportunity in the melanoma market.

     

    Their pipeline looks quite good with several products in Phase III status. The stock moved up 3.7% today.
    18 Jun 2013, 11:54 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    NVAX article:

     

    http://seekingalpha.co...
    28 Jun 2013, 11:41 AM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    Nice article, LT.
    The graphic included in the piece says a lot_

     

    WT
    28 Jun 2013, 01:01 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    This piece on Cramer tonight- (CYTK) and others-

     

    http://bit.ly/1awnl3f
    1 Jul 2013, 07:11 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    8:26 AM Data from a dose-ranging Phase 1 study of a respiratory syncytial virus vaccine candidate from Novavax (NVAX) shows that "all subject groups receiving … the [treatment] exhibited antibody responses against RSV at 28 and 56 days post-immunization." Shares +5.7% premarket. (PR) Comment! [Healthcare, On the Move
    2 Jul 2013, 08:33 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » (VICL) has been beaten down lately. Today, it crossed it's upper Bollinger and is at its 50 day MA. It might be starting a breakout... I suggest keeping an eye on it. It's up 11% since my purchase on the 11th.
    2 Jul 2013, 06:21 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    >FPA-

     

    Thanks for that heads-up. I have a position in VICL just to monitor stock activity.

     

    MACD is on the upside w/increasing volume- Good sign. RSI above 50 but money flow is not with the buy side. Possibly selling on a little strength?

     

    Will see about adding to it if I have any money left after LINE.
    2 Jul 2013, 08:18 PM Reply Like
  • Windwood Trader
    , contributor
    Comments (2707) | Send Message
     
    Happy Fourth of July, everyone-
    Be safe and well.
    4 Jul 2013, 12:24 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » Happy Fourth WT!!
    4 Jul 2013, 02:21 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Happy 4th Everyone
    4 Jul 2013, 05:42 PM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    Stem cell R&D is gaining with startling find,
    http://yhoo.it/14uEVjf
    5 Jul 2013, 04:49 AM Reply Like
  • LT
    , contributor
    Comments (4885) | Send Message
     
    MERS virus has lower pandemic risk than SARS...not sure I believe it but here it is:

     

    http://reut.rs/12KJu4z
    5 Jul 2013, 06:21 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5972) | Send Message
     
    Author’s reply » Link to new concentrator:
    http://tinyurl.com/kuk...
    6 Jul 2013, 03:18 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.